New Options for Overcoming Resistance to Anti-VEGF Therapy in HCC

Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shares his expert opinion on the importance of the phase III IMbrave150 trial, which evaluated a targeted therapy combination in patients with hepatocellular carcinoma.<br /> &nbsp;

Wasif M. Saif, MD, deputy physician in chief at the Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell,shares his expert opinion on the importance of the phase III IMbrave150 trial (NCT03434379), which evaluated a targeted therapy combination in patients with hepatocellular carcinoma (HCC).

The IMbrave150 trialis interesting because it allows the field to move beyond sorafenib (Nexavar) and nivolumab (Opdivo), 2 targeted agents that have been approved by the FDA under certain indications for HCC, says Saif. Because HCC is an intense disease, it is sometimes necessary to use more than 1 drug to treat the disease. In IMbrave150, the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) is compared to sorafenib in patients with untreated locally advanced or metastatic HCC.